Skip to content
Screener

Whitehawk Therapeutics WHWK Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue-
EPS-$0.32Beat by $0.04
EPS estimate-$0.36

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.27

Financials

Q1 2026

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$162.83M—

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Current ratio11.4×-7.6×

Segments

By segment

See full
Reportable--100%

FAQ

When did Whitehawk Therapeutics report Q1 2026 earnings?
Whitehawk Therapeutics (WHWK) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Whitehawk Therapeutics's Q1 2026 revenue and EPS?
Whitehawk Therapeutics reported revenue of - and eps of $-0.32 for Q1 2026.
Did Whitehawk Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.36 by $0.04.
How did Whitehawk Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $7.1M a year earlier and eps grew 11.1% from $-0.36.
Where can I find Whitehawk Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210615) and the 10-Q periodic report (0001193125-26-212075) directly on SEC EDGAR. The filing index links above go to sec.gov.